Raiza Rossi

Dr. Raiza Rossi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2023 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
CMCatherine Mezzacappa
Catherine Mezzacappa
RRRaiza Rossi
Raiza Rossi
AJAriel Jaffe
Ariel Jaffe
TTTamar H. Taddei
Tamar H. Taddei
MSMario Strazzabosco
Mario Strazzabosco
Background: Hepatocellular carcinoma (HCC) incidence and outcomes vary across populations in the United States, but few studies evaluate local drivers of observed disparities. We measured HCC incidence at the community level and assessed community-level HCC risk factors with the goal of informing resource allocation to improve early case detection, which is associated with improved outcomes. Methods: Clinical and demographic data including census tract of residence for all adults diagnosed with HCC in the Connecticut Tumor Registry between 2008 and 2019 were combined with publicly available U.S. Census and Centers for Disease Control and Prevention (CDC) data at the ZIP Code tabulation area (ZCTA) level. The average annual incidence of HCC was calculated for each ZCTA and associations between community-level characteristics, HCC incidence, stage at diagnosis, and survival were evaluated. Results: Average annual HCC incidence during the study period was 8.9/100,000 adults and varied from 0 to 97.7 per 100,000 adults by ZCTA. At the community level, lower rates of high school graduation, higher rates of poverty, and rural community type were associated with higher HCC incidence. Persons with HCC living in the highest incidence ZCTAs were diagnosed at a younger age and were less likely to be alive at 1, 2, and 5 years after diagnosis. Conclusions: Community-level socioeconomic factors are strongly associated with HCC incidence and survival in Connecticut. Impact: This reproducible geo-localization approach using cancer registry, Census, and CDC data can be used to identify communities most likely to benefit from health system investments to reduce disparities in HCC.

12 April 2024 in Substance use & addiction journal
Verified
Journal Article
Closed access
RRRaiza Rossi
Raiza Rossi
CCChristopher J. Cutter
Christopher J. Cutter
MBMark Beitel
Mark Beitel
MCMikah Covelli
Mikah Covelli
DFDavid A. Fiellin
David A. Fiellin
DBDeclan T. Barry
Declan T. Barry
Many patients who receive treatment for opioid use disorder (OUD) report experiencing chronic pain (CP), which is associated with high levels of ongoing nonmedical opioid use and low retention in OUD treatment. In pilot studies of patients with OUD receiving buprenorphine or methadone who had CP, cognitive behavioral therapy (CBT) attenuated nonmedical opioid use compared with treatment-as-usual (TAU), but patients in both treatment arms exhibited similar pain improvements. Adding exercise and stress reduction to this model may augment pain-related outcomes. With funding from National Institutes of Health, we plan to conduct a randomized clinical trial of 316 patients with OUD and CP to test the effectiveness of TAU compared with Stepped Care for Patients to Optimize Whole Recovery (SC-POWR) to reduce nonmedical opioid use and pain (primary outcomes) (Aim 1) and decrease pain intensity and interference, alcohol use, anxiety, depression and stress, and improve sleep (secondary outcomes) (Aim 2). Eligible participants will be randomized to receive TAU (buprenorphine or methadone and at least once a month individual or group counseling) or SC-POWR (ie, TAU and up to 12 CBT sessions) for 24 weeks. Based on prespecified nonresponse criteria, SC-POWR may be stepped up at week 6 to receive onsite weekly group sessions of exercise (Wii Fit, Tai Chi) and “stepped up” again at week 15 to receive weekly group sessions of stress reduction (relaxation training, auricular acupuncture). They will be followed for another 24 weeks to evaluate durability of treatment response for illicit opioid use, alcohol use, pain, anxiety, depression, stress, sleep, and retention in medications for OUD (Aim 3).

16 December 2025 in Current Cardiology Reports
Verified
Journal Article
Closed access
PDF file
RRRaiza Rossi
Raiza Rossi
ANArmin Nouri
Armin Nouri
ZAZafer Akman
Zafer Akman
SNShefa Arya Nezhad
Shefa Arya Nezhad
ADAbdulla A. Damluji
Abdulla A. Damluji
MNMichael G Nanna
Michael G Nanna

2 July 2026 in American Heart Journal
Verified
Journal Article
Closed access
SMSridhar Mangalesh
Sridhar Mangalesh
ZAZafer Akman
Zafer Akman
ANArmin Nouri
Armin Nouri
GBGolsa Babapour
Golsa Babapour
SNShefa Arya Nezhad
Shefa Arya Nezhad
MNMichael G Nanna
Michael G Nanna

1 June 2026 in Annals of Internal Medicine
Verified
Journal Article
Closed access
SMSridhar Mangalesh
Sridhar Mangalesh
RRRaiza Rossi
Raiza Rossi
ANArmin Nouri
Armin Nouri
ADAbdulla A. Damluji
Abdulla A. Damluji
MNMichael G Nanna
Michael G Nanna

26 August 2026 in JACC: Advances
Verified
Journal Article
Open access
RRRaiza Rossi
Raiza Rossi
PLPei-Lun Lee
Pei-Lun Lee
RHRebecca Hsieh
Rebecca Hsieh
JSJacqueline Sandoval
Jacqueline Sandoval
YJYasser Jamil
Yasser Jamil
MNMichael G. Nanna
Michael G. Nanna